India’s problem of overtreatment, overmedication

1. At a Glance

• Overtreatment / overmedication means tests, prescriptions and procedures that bring no net benefit to the patient. It usually happens as a chain: a test finds an incidental abnormality, which leads to more tests, then a diagnosis, then a prescription that may become permanent [1].
• What starts as prevention can end in long-term medication or surgery. Modern medicine can now do more than ever, and that same capacity makes it "tempting" to overtreat [1].
• India's paradox: overtreatment exists alongside undertreatment. Some people get unnecessary interventions while many others still lack essential primary care, affordable medicines and timely treatment [1].
• UPSC relevance: the topic connects to health-system governance (GS-II), antimicrobial resistance (AMR) (GS-III), out-of-pocket spending and medical ethics (GS-IV). Irrational antibiotic use is a named concern in India's AMR containment policy [2][3].

2. Why in the News

• 14 October 2026: The Hindu (Chennai edition, p. 12) ran an op-ed, "India's problem of overtreatment, overmedication", by Chandrakant Lahariya, a practising physician [1].
• Lahariya wrote 'Pill-Free: You Don't Need Everything You Have Been Prescribed' (2026) [1].
• The op-ed's main claim is that unnecessary tests, prescriptions and procedures form a growing overtreatment problem in India [1].

3. Background & Evolution

• Driving rationale: better diagnostics (earlier detection, scans that reveal "invisible abnormalities") and more available interventions have increased both the ability and the incentive to do more [1].
• 2016: a review in the National Medical Journal of India found that routine health-check packages often include unwarranted tests. These can cause false positives, anxiety, further investigations, overdiagnosis and overtreatment [1].
• Antibiotics: the WHO India country office says over-the-counter (OTC) sales and purchases on invalid prescriptions are a major focus of India's national policy for AMR containment [2].
• State-level response: Delhi's State Action Plan to Combat AMR (SAP-CARD) names the drivers of irrational antibiotic use and sets out containment at state level [3].

4. Core Static Facts

Item	Fact
Overtreatment (definition in source)	A chain of incidental finding → more tests → diagnosis → possibly lifelong prescription [1]
Cascade of care	Excessive screening or diagnostic testing that sets off follow-on interventions. The op-ed calls it the "first driver" of overtreatment [1]
Overdiagnosis	Diagnosing conditions that would not have harmed the patient. Named as an outcome of unwarranted health-check tests [1]
Evidence base cited	National Medical Journal of India review, 2016, on health-check packages [1]
AMR policy focus	OTC and invalid-prescription antibiotic sales [2]
Implementation gap	Strategies "remain spotty"; trained pharmacists are scarce in rural areas [2]
Drivers of irrational antibiotic use (SAP-CARD)	Heavy patient load; little time for consultation or counselling; perceived patient demand; diagnostic uncertainty; over-reliance on antibiotics; weak infection prevention and control (IPC); fear of losing patients; economic incentives from pharmaceutical companies; lack of continuing medical education [3]
Price distortion example	Gemifloxacin, a reserved antibiotic, costs less than first-line options, which encourages its misuse [3]

5. Multi-Dimensional Analysis

Economic

• Unwarranted tests in health-check packages add costs and set off further paid investigations [1].
• Pharmaceutical companies' economic incentives are a recognised driver of irrational prescribing [3].
• Mispricing pushes prescribers toward the wrong drugs: a reserved antibiotic (gemifloxacin) is cheaper than first-line drugs [3].

Social / Equity

• Dual burden: overtreatment for some, and missing primary care, affordable medicines and timely treatment for others [1].
• Rural areas have few trained pharmacists, which weakens control over OTC antibiotic sales [2].
• Perceived patient demand and fear of losing patients push doctors to prescribe [3].

Scientific / Public Health

• False positives from routine screening lead to anxiety and overdiagnosis [1].
• Overuse of antibiotics drives AMR, the central concern of India's national containment policy [2].
• Weak infection prevention and control (IPC) practice adds to antibiotic dependence [3].

Ethical / Governance

• Industry incentives and supplier-induced demand create a conflict of interest [3].
• Lack of continuing medical education keeps outdated prescribing habits in place [3].
• Policy exists but implementation "remains spotty", which is a regulatory enforcement gap [2].

Administrative

• Heavy OPD patient loads leave little consultation time, so doctors default to prescribing [3].
• Containment depends on states, as Delhi's SAP-CARD shows [3].

6. Recent Developments (last 12–18 months)

• 2026: Lahariya published Pill-Free: You Don't Need Everything You Have Been Prescribed [1].
• 14 October 2026: The Hindu op-ed framed overtreatment as a systemic problem in India, coexisting with undertreatment [1].
• The retrieved sources had no other dated developments from the last 12–18 months. Check fresh PIB releases on AMR and drug regulation before the exam.

7. Prelims Hooks

• Overtreatment usually works as a cascade: incidental finding → test → diagnosis → prescription [1].
• The op-ed names unnecessary testing (screening and diagnostic) as the first driver of overtreatment [1].
• A 2016 review in the National Medical Journal of India flagged unwarranted tests in routine health-check packages [1].
• Outcomes of unwarranted screening: false positives, anxiety, further investigations, overdiagnosis, overtreatment [1].
• In India, overtreatment coexists with undertreatment [1].
• OTC antibiotic sales and invalid-prescription purchases are a major focus of India's national AMR containment policy [2].
• SAP-CARD stands for the State Action Plan to Combat Antimicrobial Resistance in Delhi [3].
• Gemifloxacin is a reserved antibiotic, yet it is priced below first-line options [3].
• SAP-CARD lists "economic incentives from pharmaceutical companies" as a driver of irrational antibiotic use [3].
• A shortage of trained pharmacists in rural areas weakens OTC regulation [2].

8. Why the Doctor Gets Punished but the Drug Company Mostly Does Not

• The 2024 marketing code stops companies from bribing doctors, but it is not a law passed by Parliament
• The Department of Pharmaceuticals notified the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 on 12 March 2024. It bars drug companies from giving doctors, or their family members, gifts, money, hospitality or paid travel [5].
• The earlier code was voluntary. The government says the 2024 code is mandatory [5].

• Petitioners in the Supreme Court argued that there is still no statutory mechanism (a penalty written into an Act of Parliament) to punish companies that offer these inducements [4].

• So the penalty falls mainly on one side

• The Centre told the Court that existing rules already allow disciplinary action against doctors who accept gifts or trips [4].
• The company that pays sits under a departmental code, not a law, so the penalty it faces is lighter.

• The incentive that SAP-CARD names as a driver, "economic incentives from pharmaceutical companies", therefore stays strong on the supply side [3].

• The first enforcement case shows how light the penalty can be

• In December 2024, AbbVie Healthcare India was reprimanded (formally warned) for sponsoring "extravagant pleasure trips" abroad for 30 doctors [6].

• In this first case the penalty was a warning, not a fine. A company may simply count that as a cost of doing business.

• The Supreme Court has now stepped in

• In October 2026 the Court directed the Centre to set up a committee to examine and recommend statutory regulations for pharma marketing [4].
• For the exam: this is the live governance angle on overmedication. The question is whether India's rules will move from "guidelines for doctors" to "law for companies".

9. The Counter-Case: In a Poor Country, Isn't More Testing Safer?

• The strongest objection
• India's bigger problem is often too little care: missing primary care, unaffordable medicines, late treatment [1].
• A campaign to "test less, prescribe less" could make poor patients even more hesitant to seek care. Then diseases get caught later.

• Early detection through scans and tests is also one of modern medicine's real gains [1].

• What is right about it

• Overtreatment and undertreatment exist side by side in India [1]. A message that only says "do less" would hurt the undertreated half.

• Some fear of "losing patients" and some "diagnostic uncertainty" are real clinical pressures, not just greed [3].

• Why it still does not defend overtreatment

• The 2016 review did not criticise testing in general. It found that tests bundled into routine health-check packages were often unwarranted, and that they caused false positives, anxiety and overdiagnosis (correctly finding a condition that would never have harmed the person) [1].
• The question is not how many tests are done but which ones. A test that matches the patient's symptoms and risk helps. A test sold as part of a fixed package often does not.

• Overtreatment also feeds undertreatment. Money spent on unneeded tests and drugs is money not spent on needed care. And a reserved antibiotic used today because it is cheap may stop working for the patient who really needs it tomorrow [3][2].

• How to write it in Mains: argue for appropriate care, meaning the right care for the right person, rather than for "less care".

10. What We Still Cannot Measure

• There is no national figure for how much overtreatment India has
• The op-ed's evidence is one 2016 review of health-check packages plus a physician's clinical experience [1].

• So the claim that the problem is "growing" is an expert judgement, not a measured trend [1].

• Antibiotic data is better, but old and uneven

• The WHO India document on AMR policy is about five years old [2].

• SAP-CARD covers only Delhi [3], so it cannot show how other states perform.

• Why this matters for your answer

• Do not write "X% of tests in India are unnecessary". No source in this note supports a number like that.
• Write instead that the drivers are well documented [3], but the scale is not measured, and that this missing data is itself a gap in governance.

11. Who Must Do What to Cut Unneeded Pills and Tests

• Centre: turn the marketing code into law, with penalties for companies
• The committee the Supreme Court has ordered [4] should recommend fines for companies, not only action against doctors.

• Why: today the doctor who takes a gift faces discipline, while the company that gives it faces a reprimand [4][6].

• Drug price regulator: stop reserve antibiotics being the cheap option

• Gemifloxacin, a reserve antibiotic, is cheaper than first-line drugs, so the market pushes doctors toward the wrong drug [3].

• The National Pharmaceutical Pricing Authority (NPPA), which sets drug prices, should review prices by class so that last-resort antibiotics never cost less than first-line ones.

• States: copy the Delhi model and fix the pharmacist gap

• Delhi's SAP-CARD shows that a state can map its own drivers of irrational antibiotic use and plan a response [3].

• Other states need similar plans, and should post trained pharmacists in rural areas, where over-the-counter antibiotic control is weakest [2].

• Medical regulators and hospitals: give doctors time and updated training

• Heavy OPD load and a lack of continuing medical education (regular training after a doctor qualifies) are named drivers [3].

• More primary-care staff cuts the load per doctor. Required CME on rational prescribing updates old habits.

• Health-check package providers: tests must match the patient's risk

• The 2016 review shows that fixed packages carry unwarranted tests [1].
• Regulators could require packages to follow standard screening guidance, not a "more tests = better value" sales pitch.

12. Anchors for Answers

• Data: 30 doctors sent on pharma-sponsored "extravagant pleasure trips" abroad; AbbVie reprimanded, Dec 2024, in the first UCPMP enforcement case [6]
• Report/Committee: National Medical Journal of India review (2016) on unwarranted tests in health-check packages [1]; Supreme Court-directed committee on statutory pharma-marketing rules (October 2026) [4]
• Law/Case: Uniform Code for Pharmaceutical Marketing Practices 2024 (notified 12 March 2024) [5]; Supreme Court direction to the Centre to frame statutory rules (2026) [4]
• Scheme: Delhi's SAP-CARD, a state-level AMR plan that names the drivers of irrational antibiotic use [3]; national AMR containment policy targeting OTC and invalid-prescription sales [2]

13. Mains Relevance

• GS-II: Issues relating to development and management of Social Sector/Services relating to Health; Government policies and interventions.
• GS-III: Science & Technology, specifically awareness in biotechnology and health; AMR as a public-health security issue.
• GS-IV: Ethics in public and private relationships; conflict of interest; professional ethics of doctors.
• Question stems: 1. India faces the paradox of overtreatment and undertreatment at the same time. Examine the drivers of this dual burden and suggest health-system reforms. (250 words) 2. Irrational use of antibiotics is as much a governance failure as a clinical one. Discuss with reference to India's AMR containment efforts. (250 words) 3. Supplier-induced demand in healthcare raises serious ethical questions. Analyse the role of incentives, regulation and medical education in curbing overmedication. (GS-IV, 150 words)

14. Related Topics to Study Next

These were not verified in the retrieved sources. Check them against official sources before use.

• National Action Plan on AMR (NAP-AMR) and the One Health approach: the policy framework behind OTC antibiotic control [2].
• Schedule H / H1 of the Drugs Rules and the "Red Line" antibiotic labelling campaign: the regulatory tools against OTC antibiotic sales.
• WHO AWaRe classification (Access / Watch / Reserve): explains why a "reserved" antibiotic like gemifloxacin should not be cheap or widely used [3].
• Generic prescribing norms and Jan Aushadhi: affordability and rational-use links.
• Clinical Establishments Act and standard treatment guidelines: regulation of private-sector diagnostics and procedures.
• Out-of-pocket expenditure / National Health Accounts: the financial burden that unnecessary tests and drugs add to.
• Ayushman Bharat: Health & Wellness Centres / Ayushman Arogya Mandirs: the primary-care gap behind undertreatment [1].
• Caesarean-section rates (NFHS): a classic example of procedural overtreatment in India.

15. NCERT Concepts to Revise

• Screening (Economy): Health-check packages screen with unnecessary tests, causing false positives, overdiagnosis and cascades of follow-on care.
• Services (Economy): Healthcare is a service where the provider knows more than the patient, enabling unnecessary tests and prescriptions.
• Private sector (Economy): Private diagnostics, hospitals and pharma profit motives drive incentives behind unnecessary tests, procedures and drug prescriptions.
• Governance (Polity): Spotty enforcement of antibiotic rules and AMR policy shows overmedication as a governance failure, not only a clinical one.
• Equity (Geography): Overtreatment for some alongside missing primary care for others is an unequal-access problem.
• National Family Health Survey (Geography): NFHS data gives health indicators, including procedural overtreatment examples such as caesarean rates, useful for supporting arguments.

16. Common Errors / Trap Areas

• Overdiagnosis ≠ misdiagnosis: overdiagnosis is a correct diagnosis of a condition that would never have caused harm [1].
• Treating overtreatment as only a rich or urban problem: in India it coexists with undertreatment [1].
• Assuming cheaper always means rational: the low price of a reserved antibiotic (gemifloxacin) drives misuse [3].
• SAP-CARD is a Delhi state plan, not the national AMR plan [3].
• Blaming only patients or only doctors: the documented drivers are systemic, including patient load, industry incentives, gaps in continuing medical education and weak IPC [3].